HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symrise appointments

This article was originally published in The Rose Sheet

Executive Summary

Publicis Advertising exec Elizabeth O'Keefe joins the fragrance and flavor house as marketing VP for fine fragrances, North America, company reports. She will be responsible for creative development and marketing of all brands in the U.S. fine fragrance division and will be based in New York. She previously led development and execution of L'Oréal's Garnier Fructis launch in the U.S. while at Publicis. Joy Atkinson also joins Symrise as VP, U.S. consumer product sales for the fragrance division, from Firmenich, where she spent nine years...

You may also be interested in...



Symrise

Fragrance manufacturer has promoted Joy Atkinson president of the U.S. fine fragrances business, effective Jan. 3, company reports. Exec assumes responsibilites formerly handled by Kathy Cullin, who was appointed Global President of Fine Fragrances in October. Atkinson joined Symrise in July and currently serves as VP of sales for the U.S. consumer products fragrance division (1"The Rose Sheet" July 12, 2004, In Brief). Atkinson has strong history of sales and marketing on the beauty and fragrance manufacturing side, company notes. Prior to joining Symrise, Joy worked for Firmenich, where she was global account manager for Avon....

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel